Rezolute, Inc. Appoints Davelyn Hood to Its Leadership Team as Director, Scientific and Patient Affairs
May 20, 2021 at 04:30 pm IST
Share
Rezolute, Inc. announced the addition of Davelyn Hood, MD, to its leadership team as Director, Scientific and Patient Affairs. In her new role, Dr. Hood will be a key member of the team in furthering the development of RZ358, Rezolute’s monoclonal antibody currently being evaluated in a Phase 2b clinical trial to treat congenital hyperinsulinism, a rare disease that is the most common cause of persistent low blood sugars in children. Dr. Hood is a long-standing member of Congenital Hyperinsulinism International, where she has led international collaboration and communication efforts around ensuring increased access to treatment. In addition to over a decade of experience working on initiatives related to congenital hyperinsulinism, Dr. Hood has also served in various scientific and leadership capacities, including the President of the Board of Directors and Principal Investigator for the patient reported Hyperinsulinism Global Registry, aimed at consolidating patient data for research purposes.
Rezolute, Inc. is a clinical-stage biopharmaceutical company, which is developing therapies for metabolic diseases related to chronic glucose imbalance. The Companyâs lead clinical asset, RZ358, is in late-stage development for the treatment of congenital hyperinsulinism (HI), an ultra-rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas in Phase III. RZ358 is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat and muscle. Its second clinical asset, RZ402, is an oral plasma kallikrein inhibitor (PKI) being developed as a therapy for the chronic treatment of diabetic macular edema (DME) in Phase II. RZ402 is designed to be a once daily oral therapy for the treatment of DME and unlike the anti-VEGF therapies, RZ402 targets the Kallikrein-Kinin System to address inflammation and vascular leakage.
REZOLUTE, INC. 
